Greenwich LifeSciences Inc

NASDAQ:GLSI  
8.48
+0.07 (+0.83%)
Products, Regulatory

Greenwich Lifesciences Provides Updates On Upcoming Phase III Clinical Trial & Asco Meeting

Published: 05/23/2022 11:47 GMT
Greenwich LifeSciences Inc (GLSI) - Greenwich Lifesciences Provides Updates on Upcoming Phase Iii Clinical Trial & Asco Meeting.
Greenwich Lifesciences Inc - FDA Review of Manufacturing Plans and Pharmacy Procedures Associated With a Recently Placed Clinical Hold on Flamingo-01 Phase Iii Clinical Trial is Underway.
Greenwich Lifesciences Inc - Formal Feedback From FDA Expected Shortly.
Greenwich Lifesciences Inc - Prepared to Address FDA Manufacturing and Pharmacy Procedure Hold Issues So That Flamingo-01 Can Commence As Soon As Possible.